Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,014
Total Claims
$913K
Drug Cost
695
Beneficiaries
$1,314
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-7%
Cost per patient vs peers
$1,314 vs $1,411 avg
+19%
Brand preference vs peers
12.7% vs 10.6% avg
Brand vs Generic
Brand: 1,433 claims · $807K
Generic: 9,854 claims · $102K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 200 | $215K |
| Linagliptin | 45 | $57K |
| Empagliflozin | 26 | $36K |
| Rivaroxaban | 25 | $32K |
| Budesonide/Formoterol Fumarate | 63 | $30K |
| Sacubitril/Valsartan | 20 | $27K |
| Sitagliptin Phos/Metformin Hcl | 23 | $27K |
| Insulin Glargine,hum.Rec.Anlog | 52 | $27K |
| Sitagliptin Phosphate | 26 | $24K |
| Insulin Aspart | 42 | $24K |
| Mirabegron | 26 | $21K |
| Insulin Aspart | 28 | $17K |
| Insulin Glargine,hum.Rec.Anlog | 35 | $16K |
| Linaclotide | 22 | $13K |
| Semaglutide | 13 | $13K |
Prescribing Profile
Patient Profile
77
Avg Age
57%
Female
2.22
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data